Cargando…
Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma
The exponential rise in the use of immune checkpoint inhibitors (Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab) as the new standard for cancer treatment increase the incidence the immune-related adverse events due to immune activation. Endocrine immune-related adverse...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrinology Research Centre
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926137/ https://www.ncbi.nlm.nih.gov/pubmed/34004100 http://dx.doi.org/10.14341/probl12698 |